Reshma Shetty: How She Turned Biology Into a Programmable Manufacturing Platform

Reshma Shetty sits at the intersection of computer science, biology, and entrepreneurship, helping turn synthetic biology from an emerging scientific discipline into a scalable engineering platform. As a co-founder of Ginkgo Bioworks, she helped pioneer a model in which software, automation, genetic engineering, and high-throughput experimentation can be combined to make biology easier to design and manufacture.

Table of Contents

Key Takeaways

Reshma Shetty helped pioneer the idea of treating biology as an engineering discipline rather than only as an observational science.
Ginkgo Bioworks applies software, automation, robotics, and genetic engineering to make biological design more scalable.
The biological foundry model shifts the focus from creating one product to building infrastructure capable of supporting many biological products.
Automated experimentation can generate data that strengthens the design-build-test-learn cycle at the heart of modern synthetic biology.
Shetty’s biggest innovation may be demonstrating how biological systems could become programmable and scalable manufacturing platforms.

The Idea That Biology Could Be Engineered

When Reshma Shetty arrived at MIT, she already had a computer science background. Her work in biological engineering exposed her to a fundamentally different kind of programming: instead of writing instructions for computers, researchers were trying to write genetic instructions for living cells.

That idea became central to her career.

During her graduate work, Shetty and her collaborators explored the emerging field of synthetic biology, working toward a future in which biological systems could be designed with some of the systematic thinking used in engineering and computing.

The problem was that biology was still remarkably difficult to engineer.

Experiments could take substantial time, many designs failed, and researchers could only explore a relatively small number of possibilities. Shetty later explained that Ginkgo was partly born from this frustration. If biology was going to become an engineering discipline, researchers needed better tools for designing, building, testing, and learning from biological systems.

That observation would become the foundation of one of the most ambitious ideas in modern biotechnology.

From Computer Science to Synthetic Biology

Shetty’s educational background gave her an unusual perspective on biological problems.

She earned a bachelor’s degree in computer science from the University of Utah before pursuing a Ph.D. in biological engineering at MIT. During her time in synthetic biology, she became involved in the broader effort to make biological engineering more accessible, standardized, and repeatable.

In 2006, she was an advisor to the iGEM competition, where she became known for an experiment involving bacteria engineered to produce banana- and mint-like smells. It sounds playful, but the underlying concept was serious. Researchers were beginning to demonstrate that biological systems could be modified according to designed genetic instructions.

For Shetty, this represented something much bigger than an interesting laboratory experiment. It suggested that cells could become programmable platforms.

The challenge was figuring out how to make that programming process faster, more reliable, and more scalable.

Building Ginkgo Bioworks

In 2008, Shetty joined Tom Knight, Jason Kelly, Barry Canton, and Austin Che in co-founding Ginkgo Bioworks. The company’s mission was straightforward but highly ambitious: make biology easier to engineer.

Rather than focusing exclusively on developing one drug or one consumer product, the founders pursued a platform approach. The idea was to build the infrastructure required for other companies to engineer organisms.

That meant combining genetic engineering with software, automation, robotics, data collection, and standardized workflows.

It was an unconventional proposition at the time. Investors were initially skeptical, and the founders struggled to raise conventional startup capital. Instead, they bootstrapped Ginkgo during its early years, gradually developing the tools and processes that would eventually demonstrate the viability of their model.

The company’s early persistence illustrates an important lesson in deep-tech entrepreneurship: sometimes the commercial opportunity becomes visible only after the underlying infrastructure has been built.

The Innovation Behind the Innovation

The most interesting part of Shetty’s story is arguably not a particular biological invention. It is the engineering system she helped build around biology.

Traditional biological research has often depended heavily on human expertise and manual laboratory work. Ginkgo’s approach was to automate many of those processes and create a repeatable design-build-test-learn cycle.

Design → Build → Test → Learn → Repeat

Researchers can computationally design genetic instructions, construct them, introduce them into cells, test how the resulting organisms behave, collect the data, and use those results to inform the next generation of designs.

Ginkgo’s foundry model embodied this philosophy. Its automated laboratory infrastructure combined robotics, software, databases, and laboratory equipment to accelerate biological engineering processes that traditionally required substantial manual work.

This is where Shetty’s computer-science background becomes particularly important. The goal was not simply to create a better organism; it was to create a better system for creating organisms.

That distinction is fundamental.

Turning Cells Into Manufacturing Platforms

One way to understand Shetty’s innovation is to compare biological engineering with semiconductor manufacturing.

A computer-chip company does not simply design one chip and stop. It develops sophisticated manufacturing infrastructure that allows increasingly complex designs to be produced and tested.

Shetty and the Ginkgo team applied a similar philosophy to biology.

Their “foundry” model was designed to give scientists access to the equipment and automation needed to create organisms for different applications. Early examples included engineered microbes capable of producing ingredients used in areas such as fragrances, flavors, nutrition, and industrial chemicals.

The potential was much broader than any single product.

If engineers could reliably program microbes to manufacture useful molecules, biology could potentially become a new form of industrial production.

Instead of extracting certain materials from plants, synthesizing them through conventional chemistry, or relying on environmentally intensive supply chains, companies could potentially use engineered organisms as miniature biological factories.

That is the larger vision behind synthetic biology as an industrial technology.

Scaling the Design-Build-Test Cycle

The real advantage of automation is not simply speed. It is scale.

A human researcher can only conduct a limited number of experiments. Automated systems can potentially run many more iterations, creating larger datasets that can reveal which biological designs work and which do not. This creates a feedback loop.

More designs produce more experiments. More experiments generate more data. More data can improve future designs.

Shetty has described Ginkgo’s approach as combining computer-aided engineering, gene synthesis, automation, and analytical technologies to search biological design space more cheaply and at greater scale.

That approach also creates an interesting connection between synthetic biology and modern AI.

AI systems are increasingly useful when large amounts of structured data can be generated and fed back into models. In biological engineering, automated experimentation can create precisely the kind of data needed to improve computational design.

The laboratory therefore becomes not just a place where experiments happen, but a data-generating engine for biological innovation.

From Scientific Experiment to Business Platform

Shetty’s contribution also demonstrates why platform businesses can be particularly powerful in deep technology.

A conventional biotech startup might develop one therapeutic candidate, one diagnostic technology, or one biological product. Ginkgo’s model was different. Its infrastructure could potentially support many customers working on many different biological problems.

That creates a broader business proposition: rather than betting everything on one biological outcome, the company builds the capabilities required to solve a large class of biological engineering problems.

The approach helped Ginkgo attract customers interested in areas ranging from industrial biotechnology to agriculture and pharmaceuticals.

This is an important entrepreneurial lesson: sometimes the most valuable innovation is the platform underneath the products.

Making Biology More Like an Engineering Discipline

Shetty’s broader vision is perhaps best understood as an attempt to change how humans interact with biology.

For much of modern history, people have learned to manipulate biological systems through observation, experimentation, breeding, chemistry, and increasingly sophisticated molecular biology.

Synthetic biology introduces another possibility: What if biological systems could be designed with greater predictability? What if engineers could specify a desired function, construct a biological system capable of performing it, test the result, and systematically improve it?

That is still an extraordinarily difficult challenge.

Biology is not a computer. Living systems are complex, adaptive, and influenced by countless variables. But Shetty’s work argues that complexity does not mean biology cannot be engineered.

It means engineers need better tools.

The Business of Building the Bioeconomy

The significance of Shetty’s work extends beyond Ginkgo itself.

Synthetic biology could eventually influence manufacturing, agriculture, materials, food, chemicals, pharmaceuticals, and environmental technologies. Biological manufacturing could potentially create products using renewable feedstocks, reduce dependence on difficult supply chains, or produce molecules that are difficult or expensive to manufacture through conventional methods.

The opportunity is therefore not simply to build a new category of biotechnology companies. It is to build a bioeconomy in which biological systems become another major manufacturing technology.

Shetty has argued that biology has enormous potential to address challenges ranging from medicine to agriculture and environmental remediation.

That makes her story particularly relevant to today’s innovation landscape, where the boundaries between software, AI, robotics, manufacturing, and biology are becoming increasingly blurred.

The Innovator Behind the Infrastructure

Today, Ginkgo’s official leadership materials identify Shetty as its President and a member of its board. Ginkgo says she has been active in synthetic biology for more than 15 years and has helped the company grow to more than 500 people. She served as Chief Operating Officer through 2025.

Her career demonstrates a different type of innovation from the conventional startup story. She did not set out simply to invent a new consumer product. She helped create an entirely different method for producing biological innovation.

That distinction matters.

The next generation of biotechnology may not be defined by a single breakthrough organism or molecule. It may instead be defined by increasingly sophisticated systems capable of designing, testing, and improving biological systems at unprecedented scale.

Reshma Shetty was among the entrepreneurs who recognized that possibility early. Her central insight remains remarkably simple: if biology is going to become an engineering discipline, engineers need better ways to engineer it.

And sometimes, the biggest innovation is building the infrastructure that allows thousands of other innovations to follow.

FAQs

Who is Reshma Shetty?

Reshma Shetty is a computer scientist, biological engineer, entrepreneur, and co-founder of Ginkgo Bioworks. She holds a Ph.D. in Biological Engineering from MIT and has spent more than 15 years working in synthetic biology.

What is Ginkgo Bioworks?

Ginkgo Bioworks is a biotechnology company focused on engineering organisms using genetic engineering, automation, software, and laboratory infrastructure. Rather than concentrating on one biological product, its platform is designed to support biological engineering across multiple industries.

What is a biological foundry?

A biological foundry is automated laboratory infrastructure designed to accelerate the design, construction, and testing of engineered organisms. Ginkgo’s foundry model demonstrates how robotics and software can automate processes that traditionally required substantial manual laboratory work.

Why is synthetic biology important?

Synthetic biology could allow scientists and engineers to design biological systems that manufacture useful products, potentially transforming areas such as medicine, agriculture, materials, chemicals, and food. Its long-term significance comes from treating biology as something that can increasingly be designed and engineered.

What makes Reshma Shetty an innovator?

Shetty’s distinctive contribution is combining computer-science thinking with biological engineering and entrepreneurship. Her work helped demonstrate that software, automation, standardized processes, and high-throughput experimentation could become foundational infrastructure for a scalable bioeconomy.

Sources: